Mondaycom Ltd vs Summit Therapeutics Inc — how do they compare? Mondaycom Ltd trades at $73.54 (market cap $3.24B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Summit Therapeutics Inc is far larger — about 3.2× Mondaycom Ltd's market cap. Which is the better fit depends on your goals.
| MNDY | SMMT | |
|---|---|---|
Market Cap | $3.24B | $10.48B |
Sector | Technology | Health |
52-Week High | $292.24 | $29.32 |
52-Week Low | $58.81 | $13.05 |
Enterprise Value | $2.21B | $9.90B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Trailing returns across standard periods
Latest headlines on both assets
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →